摘要
目的:探讨奥沙利铂联合参芪扶正注射液对原发性肝癌患者AFP,GP73及临床疗效的影响。方法:收集我院收治的原发性肝癌患者80例,随机分为对照组和实验组,每组各40例,对照组患者给予奥沙利铂联合卡培他滨化疗,实验组患者在此基础上给予参芪扶正注射液静脉滴注。观察并比较两组患者治疗前后血清AFP及GP73水平、生活质量以及临床疗效。结果:与治疗前相比,两组患者的AFP、GP73水平均下降,差异具有统计学意义(P<0.05);与对照组相比,实验组患者的AFP、GP73水平较高,生活质量提高率较高,差异具有统计学意义(P<0.05),临床治疗总有效率以及总稳定率较高,差异具有统计学意义(P<0.05)。结论:奥沙利铂联合参芪扶正注射液能够降低原发性肝癌患者AFP,GP73水平,提高患者生活质量,临床疗效较好。
Objective： To investigate the effect of the oxaliplatin combined with Shenqi Fuzheng injection on the level changes of AFP and GP73 and the clinical effect for patients with primary liver cancer. Methods： 80 patients with primary liver cancer from our hospital were selected and randomly divided into the experimental group and the control group with 40 cases in each group. Patients in the control group were treated with oxaliplatin, while the patients in the experimental group were treated with Shenqi Fuzheng injection besides the control group. Then the levels of AFP and GP73, the quality of life and the clinical effects in the two group were observed and compared before and after the treatment. Results： Compared with before treatment, the AFP and GP73 were decreased in the two groups, and the differences were statistically significant （P〈0.05）; Compared with the control group, the levels of AFP and GP73 in the experimental group were higher, and the quality of life improved rate and the clinical treatment efficiency and stable rate were higher, and the differences were statistically significant （P〈0.05）. Conclusion： Oxaliplatin combined with Shenqi Fuzheng injection can reduce the levels of AFP and GP73 for patients with primary hepatocellular carcinoma and improve the quality of life with obviously clinical curative effect.
出处
《现代生物医学进展》
CAS
2016年第22期4289-4291,4366,共4页
Progress in Modern Biomedicine
基金
2014年河北省医学科学重点计划项目(ZL20140032)
